NeuroMetrix(NURO) - 2021 Q3 - Quarterly Report

Financial Performance - Revenues for the third quarter of 2021 were $2,064.4 thousand, a 1.4% increase from $2,036.2 thousand in the same period of 2020[52] - Gross profit for the third quarter of 2021 was $1,444.6 thousand, with a gross margin of 70.0%, down from 73.6% in the prior year due to inventory charges[53][54] - Total operating expenses for the third quarter of 2021 increased by 21.4% to $2,132.5 thousand, driven by higher research and development, sales and marketing, and general and administrative costs[62] - Revenues for the nine months ended September 30, 2021 were $6,433.3 thousand, a 15.5% increase from $5,568.2 thousand in the same period of 2020[60] - Gross profit for the nine months ended September 30, 2021 was $4,679.0 thousand, with a gross margin of 72.7%, up from 70.3% in the prior year[61] Expenses - Research and development expenses for the third quarter of 2021 rose by 11.0% to $724.6 thousand, reflecting increased clinical and development costs[56] - Sales and marketing expenses for the third quarter of 2021 increased by 29.7% to $442.2 thousand, primarily due to higher personnel costs[57] - General and administrative expenses for the nine months ended September 30, 2021 increased by 20.8% to $3,254.2 thousand, mainly due to higher non-cash personnel costs[65] Cash and Liquidity - Cash and cash equivalents were $23.2 million as of September 30, 2021, serving as the principal source of liquidity for the company[67] - Cash and cash equivalents increased by $18.0 million to $23,213.5 thousand as of September 30, 2021, reflecting a 344.2% increase compared to $5,226.2 thousand on December 31, 2020[68] - Net cash used in operating activities decreased to $(1,561.2) thousand for the nine months ended September 30, 2021, compared to $(2,348.1) thousand in 2020[71] - Net cash provided by financing activities increased significantly to $19,673.6 thousand in 2021 from $4,151.0 thousand in 2020[71] - Total net cash provided for the nine months ended September 30, 2021, was $17,987.4 thousand, up from $1,802.9 thousand in 2020[71] Market and Product Information - The company’s products are cleared by the U.S. FDA and are sold in both domestic and international markets, addressing significant health issues such as chronic pain and peripheral neuropathies[46] - The company anticipates unmet needs in chronic pain management and diabetic neuropathy diagnosis and treatment, indicating potential market opportunities[72] Investment Strategy - The company does not use derivative financial instruments and focuses on preserving principal and maintaining liquidity in its investment strategy[73] - The average maturity of the company's investments is maintained at twelve months or less to minimize interest rate exposure[73] Risks and Uncertainties - The company acknowledges risks and uncertainties that may cause actual results to differ from forward-looking statements, including market acceptance and regulatory approvals[72] Operational Efficiency - Days sales outstanding (DSO) was 24 days for the quarter ended September 30, 2021, consistent with 23 days in the prior year period[69] - Inventory turnover rate improved to 2.4 turns in Q3 2021 from 1.9 turns in the prior year, driven by higher sales[70]